The Influence of a Gene Expression Profile on Breast Cancer Decisions
The Influence of a Gene Expression Profile on Breast Cancer Decisions
复制标题
DOI：
10.1002/jso.21244
复制
发表时间：
2009-05-01
影响因子：
2.5
通讯作者：
Soballe, Peter W.
中科院分区：
文献类型：
--
作者：
Henry, Leonard R.;Stojadinovic, Alexander;Soballe, Peter W.
目的：Oncotype Dx（R）复发评分（RS）通常用于雌激素受体阳性、淋巴结阴性（ER+LN-）乳腺癌患者。我们调查了RS对实际化疗管理的影响和对乳腺肿瘤学专家小组的检测效果。患者和方法：前瞻性辅助化疗建议（RS前）和实际辅助治疗（RS后）连续ER+LN-乳腺癌患者的记录。6个月后，在相同的信息下，一个由5名专家组成的小组提出了有和没有RS的辅助治疗建议，并对他们的建议进行了评价。率的面板共识，建议的变化，并在建议strength的变化进行了compared.Results：有29例患者（28名妇女）。RS结果改变了9例患者（31%）的化疗计划：13例患者中有7例（54%）最初建议化疗但没有接受，16例患者中有2例（13%）在最初建议化疗后接受了化疗。RS结果改变了7例患者（24%）的化疗建议：5/12（42%）例建议改为反对，2/17（12%）例建议改为化疗。RS增加了共识的面板10%，但没有增加化疗recommendations.Conclusions报告的强度：RS结果与现实世界的决策变化在31%的患者和24%的面板的建议，并增加面板的共识10%。然而，斯普斯卡共和国并没有加强秘书长建议的力度。《肿瘤外科杂志》2009：99：319-323.发布于2009年Wiley-liss，Inc.
Purpose: The Oncotype Dx (R) Recurrence Score (RS), is often employed in patients with estrogen receptor-positive, node negative (ER+LN-) breast cancer. We investigated the impact of the RS on actual chemotherapy administration and the effect of the assay on a panel of breast oncology experts.Patients and Methods: The prospective adjuvant chemotherapy recommendations (prior to RS) and actual adjuvant therapy (after RS) for consecutive patients with ER+LN- breast cancer were recorded. After 6 months and with the same information, a panel of five experts made adjuvant therapy recommendations with and without RS and rated the strength of their recommendations. Rates of panel consensus, recommendation changes, and changes in recommendation strength were compared.Results: There were 29 patients (28 women). RS results altered the plan for chemotherapy in 9 patients (31%): 7 of 13 patients (54%) initially recommended for chemotherapy did not receive it, and 2 of 16 (13%) received chemotherapy following initial recommendations against it. RS results changed the panel's chemotherapy recommendation in 7 patients (24%): 5 of 12( 42%) recommendations for changed to against, and 2 of 17 (12%) recommendations against changed to for chemotherapy. RS increased consensus by the panel 10%, but did not increase the reported strength in chemotherapy recommendations.Conclusions: RS results were associated with real-world decision changes in 31% of patients and 24% of panel recommendations and increased panel consensus by 10%. However RS did not increase the strength of penelist's recommendations. J. Surg. Oncol. 2009:99: 319-323. Published 2009 Wiley-liss, Inc.